CN109705220A - One plant of hybridoma cell strain for secreting anti-chlorine promazine monoclonal antibody and its application - Google Patents

One plant of hybridoma cell strain for secreting anti-chlorine promazine monoclonal antibody and its application Download PDF

Info

Publication number
CN109705220A
CN109705220A CN201910026997.0A CN201910026997A CN109705220A CN 109705220 A CN109705220 A CN 109705220A CN 201910026997 A CN201910026997 A CN 201910026997A CN 109705220 A CN109705220 A CN 109705220A
Authority
CN
China
Prior art keywords
chlorpromazine
monoclonal antibody
cell strain
hybridoma cell
chlorine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201910026997.0A
Other languages
Chinese (zh)
Inventor
胥传来
王忠兴
匡华
徐丽广
刘丽强
马伟
吴晓玲
宋珊珊
胡拥明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuxi Determine Bio Tech Co ltd
Jiangnan University
Original Assignee
Wuxi Determine Bio Tech Co ltd
Jiangnan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxi Determine Bio Tech Co ltd, Jiangnan University filed Critical Wuxi Determine Bio Tech Co ltd
Priority to CN201910026997.0A priority Critical patent/CN109705220A/en
Publication of CN109705220A publication Critical patent/CN109705220A/en
Withdrawn legal-status Critical Current

Links

Abstract

One plant of hybridoma cell strain for secreting anti-chlorine promazine monoclonal antibody and its application, belong to food safety field of immunodetection.Hybridoma cell strain D of secretion anti-chlorine promazine monoclonal antibody prepared by the present invention, has been preserved in China Committee for Culture Collection of Microorganisms's common micro-organisms center, and deposit number is CGMCC No.17304.The hybridoma cell strain D, which can secrete generation, has preferable affinity and higher sensitivity to chlorpromazine, to 50% inhibition concentration IC of chlorpromazine50For 17.2 μ g/L, it can be used for preparing the immunity detection reagent and colloidal gold strip of chlorpromazine, the detection for chlorpromazine in animal derived food provides strong detection method and means.

Description

One plant of hybridoma cell strain for secreting anti-chlorine promazine monoclonal antibody and its application
Technical field
The hybridoma cell strain for secreting anti-chlorine promazine monoclonal antibody the present invention relates to one plant and its application belong to food peace Panimmunity detection field.
Background technique
Chlorpromazine (chlorpromazine, CPZ), also known as wintermin, belong to phenothiazines, are central dopamine Receptor blocking pharmacon has the effects that calmness, antipsychotic, reduces body temperature and basic metabolism.This medicine is mainly used to town on animal doctor Quiet and antiemetic.Chlorpromazine is added in daily ration so that animal is played the role of fattening indirectly, some are illegal during animal transport Usually large dosage uses chlorpromazine to retailer, this is because chlorpromazine can reduce the maintenance needs of animal, reduces weightless and dead on the way Die rate.Large dosage uses before butchering, and can lead to a large amount of chlorpromazines and remains in animal product, the storage of chlorpromazine in animal body Product property residual can constitute potential threat to the safety of eater, can cause eater that oligoleukocythemia and agranulocytosis occurs Disease, and other adverse reactions.Therefore there are rule in European Union, Japan and China etc. to residual quantity of the chlorpromazine in animal food It is fixed.
At present detection chlorpromazine remain more conventional method have spectrophotometer method, fluorescent spectrometry, liquid chromatography, Liquid Chromatography-Mass Spectrometry and electrochemical process etc., these methods or expensive equipment or sample treatment are complicated, it is more difficult to answer extensively For in extensive high-throughput detection.And immunoassay method is with inexpensive, high-throughput, highly sensitive, opposite to technical staff It is required that the features such as low, therefore it is suitable for the rapid screening of a large amount of samples.
Summary of the invention
The hybridoma cell strain for secreting anti-chlorine promazine monoclonal antibody the purpose of the present invention is to provide one plant and its application, There is preferable affinity and sensitivity to chlorpromazine by monoclonal antibody prepared by the cell strain, can be used to establish chlorpromazine Enzyme-linked immune detection method, or establish colloidal gold immuno-chromatography test paper strip rapid detection method.
Technical solution of the present invention, has been preserved in by hybridoma cell strain D of one plant of secretion anti-chlorine promazine monoclonal antibody China Committee for Culture Collection of Microorganisms's common micro-organisms center CGMCC, address Yard 1, BeiChen xi Road, Chaoyang District, Beijing City No. 3 Institute of Microorganism, Academia Sinica, classification naming are monoclonal cell strain, preservation date on May 24th, 2018, and preservation is compiled Number CGMCC No.17304.
Anti-chlorine promazine monoclonal antibody is produced by No. D secretion of deposit number CGMCC No.17304 hybridoma cell strain It is raw.
The application of the anti-chlorine promazine monoclonal antibody, for the remaining detection of chlorpromazine in food.
Secrete hybridoma cell strain D preparation basic step of anti-chlorine promazine monoclonal antibody are as follows:
(1) preparation of haptens: by the reaction of half hydrochloride of acetylpromazine maleate and carboxylic methoxamine, synthesis one is had The chlorpromazine haptens of two carbochains.
(2) preparation and identification of immunogene: using chlorpromazine haptens as raw material, pass through the ammonia of active ester method and protein carrier Base phase connects, and after reaction, by small haptens dialysis separation comlete antigen and be not coupled, comlete antigen passes through ultraviolet Absorb scan method identification;
(3) mouse is immune: the BALB/c mouse for choosing 6-8 week old is immunized.Immunogene and freund adjuvant emulsification is complete Afterwards, mouse is immunized by subcutaneous multi-point injection, first immunisation uses Freund's complete adjuvant, and booster immunization is not exclusively helped using Fu Shi Agent, immunizing dose is the half of a preceding immunizing dose when spurt is immune, directly carries out abdominal cavity after mixing with physiological saline Injection;Each secondary immunization interval is three weeks.After third time is immune, interval blood sampling in one week detection serum titer and inhibition;
(4) cell fusion and cell strain are established: by polyethylene glycol (PEG 2000) method, making mouse boosting cell and mouse myeloma Cell fusion detects positive cell hole using indirect ELISA, and further utilize indirect competition by HAT culture medium culture ELISA method measure positive cell hole inhibitory effect, by limiting dilution assay to have the positive cell hole preferably inhibited carry out three Secondary subclone finally screens acquisition hybridoma cell strain D;
(5) it the identification of hybridoma cell strain property: is set with and is measured with ELIAS secondary antibody using mouse monoclonal Ig class/subgroup identification; IC50The measurement of value, cross reacting rate and affinity passes through ELISA method.
Beneficial effects of the present invention: (1) the anti-chlorine promazine monoclonal antibody that the present invention obtains has preferable inspection to chlorpromazine Survey sensitivity and affinity;(2) a kind of method of new synthesis chlorpromazine immunogene, synthesis step more simplifies, effectively, for the present The research of people provides the thinking and method of synthetic immunogen afterwards.
Biological material specimens preservation: one plant anti-chlorine promazine monoclonal antibody hybridoma cell strain D, it is micro- China has been preserved in Biological inoculum preservation administration committee common micro-organisms center CGMCC, in the Yard 1, BeiChen xi Road, Chaoyang District, Beijing City 3 of address Institute of microbiology, the academy of sciences, state, classification naming are monoclonal cell strain, preservation date on May 24th, 2018, deposit number CGMCC No.17304。
Detailed description of the invention
Fig. 1 is the ultra-violet absorption spectrum characterization of immunogene.
Fig. 2 is the standard suppression curve of chlorpromazine monoclonal antibody.
Specific embodiment
The following examples of the present invention are only used as the further explanation of the content of present invention, not as a limitation of the present invention interior Perhaps range.Below by embodiment, the invention will be further described.
The present invention is by being immunized mouse for chlorpromazine comlete antigen, by cell fusion, HAT selective medium culture, Cell conditioned medium is screened by indirect ELISA and indirect competitive ELISA, having finally obtained has preferable affinity and sensitive to chlorpromazine The monoclonal antibody hybridoma cell strain of degree.
Embodiment 1: the preparation that anti-chlorine promazine monoclonal antibody hybridoma cell is strain D
1, the synthesis of haptens: acetylpromazine maleate (APZ, 45 mg, 0.01 mmol) and half hydrochloride of carboxylic methoxamine (CMO, 25 mg, 0.02 mmol) is dissolved in deionized water (5 mL), and sodium acetate is added dropwise in the case where rotor stirring, Adjustment pH is 8-9, is 2-3 with 0.1 M hydrochloric acid adjustment pH, then by 15mL then by mixture in 40 DEG C of 10 h of back flow reaction Ethyl acetate is added.Ethyl acetate layer is collected, it is dry with Rotary Evaporators, obtain chlorpromazine haptens (CPZ-hapen).
2, the synthesis of comlete antigen: taking 2.2mg chlorpromazine haptens to be dissolved in 2mL dimethylformamide, and 4.5mg is added EDC(1- (3- dimethylamino-propyl) -3- ethyl-carbodiimide hydrochloride) and 3.6mg NHS(N- HOSu NHS), room Temperature stirring, activates 4h;Separately take 10mg KLH(keyhole limpet hemocyanin) it is dissolved in the CB solution (carbonate of 3mL, 0.05M, pH9.6 Buffer solution) in, above-mentioned activating solution is added dropwise in KLH solution, is stirred at room temperature after reaction overnight, 4 DEG C are dialysed three days, and -20 DEG C packing save.
3, animal immune: the BALB/c mouse of the 6-8 week old of health is selected to be immunized.Take chlorpromazine comlete antigen After the emulsification uniformly of (1mg/mL) and equivalent freund adjuvant, BALB/c mouse, every 100 μ L are immunized by subcutaneous multi-point injection.It is first It is secondary it is immune use Freund's complete adjuvant, booster immunization uses freund 's incomplete adjuvant, and immunizing dose is preceding primary when spurt is immune The half of immunizing dose is directly injected intraperitoneally after mixing with physiological saline;Each secondary immunization interval is three weeks.For the third time After immune, interval blood sampling in one week detection serum titer and inhibition;Selection inhibits best mouse, and spurt in 18 days is exempted from after exempting from five Epidemic disease prepares fusion.
4, cell fusion: after spurt immune three days, according to conventional PEG(polyethylene glycol, molecular weight 2000) method into Row cell fusion, the specific steps are as follows:
(1) sterile to take mouse spleen, it grinds and obtains splenocyte suspension by 200 mesh cell screen clothes, and carry out cell count;
(2) SP2/0 cell is collected, is suspended in RPMI-1640 basic culture solution, cell count is carried out;
(3) splenocyte and SP2/0 cell are mixed according to the counting ratio of 2-10:1, are merged after centrifugation with PEG, 1 min of time, Later according to from slowly to fast, RPMI-1640 basic culture solution is added, be suspended in after centrifugation containing 20% fetal calf serum, 2% 50 × In the RPMI-1640 screening and culturing liquid of HAT, 96 porocyte culture plates are added to, are placed in 37 DEG C, 5% CO2Incubator in cultivate.
5, cell screening and cell strain are established: carrying out RPMI-1640 screening training to fused cell within the 3rd day in cell fusion Nutrient solution partly changes liquid, carries out within the 5th day being changed entirely with the RPMI-1640 transition culture solution of 100 × HT containing 20% fetal calf serum, 1% Liquid took cell conditioned medium to be screened at the 7th day.Screen in two steps: the first step first filters out positive cell hole with indirect ELISA, It is standard items that second step, which selects chlorpromazine, carries out inhibitory effect measurement to positive cell with indirect competitive ELISA.Selection is to chlorine third Piperazine has the cell hole preferably inhibited, is subcloned using limiting dilution assay, is detected with same method.In triplicate, Obtain anti-chlorine promazine monoclonal antibody hybridoma cell strain D.
6, the preparation and identification of monoclonal antibody: taking 8-10 week old BALB/c mouse, and every mouse peritoneal injects paraffin oil 1mL;Every mouse peritoneal injection 1 × 10 after 7 days6Hybridoma collected ascites since the 7th day, and ascites is passed through octanoic acid- The purifying of saturated ammonium sulfate method, the monoclonal antibody of acquisition are placed in -20 DEG C of preservations.
It is sub- that immunoglobulin is carried out using the monoclonal antibody that mouse monoclonal subtype identification kit obtains ascites purifying Type identification, hypotype are IgG2a type, specific as shown in table 1.
The subtype identification of 1 chlorpromazine monoclonal antibody of table
Using indirect competitive ELISA method, monoclonal antibody is measured to the IC of chlorpromazine50For 3.61 μ g/L, and it is demonstrated to him The IC of Da Lafei etc.50And cross reacting rate, it is specific as shown in table 2.
2 chlorpromazine monoclonal antibody of table to chlorpromazine, fenazil, put forth energy to be close, Chlorprothixene IC50And cross reacting rate
7, antibody application: anti-chlorine promazine monoclonal antibody hybridoma cell strain D is resisted by monoclonal prepared by internal ascites Body is applied to chlorpromazine ELISA and adds recovery test, the specific steps are as follows:
(1) chlorpromazine for the 0.1 μ g/mL for using carbonate buffer solution (CBS) to dilute is coated with as coating 96 hole enzyme mark of primordial covering Plate, after every hole 100 μ L, 37 DEG C of 2 h of coating, three times with PBST washing lotion board-washing, each every 200 μ L of hole, 3 min, is patted dry every time;
(2) it is closed with the CBS containing 0.2% gelatin, every hole 200 μ L, 37 DEG C of 2 h of closing, three times with PBST washing lotion board-washing, often 200 μ L of secondary every hole, each 3min are patted dry;
(3) the chlorpromazine standard of 0,0.02,0.05,0.1,0.2,0.5,1,2 μ g/L is respectively configured with phosphate buffer (PBS) Solution.Standard solution and sample to be tested extracting solution are added separately in the ELISA Plate closed, every 50 μ L of hole, Each sample repeats 3 holes, then the 50 diluted anti-chlorine promazine monoclonal antibodies of μ L 1:16000,37 DEG C of reaction 0.5h are added in every hole Afterwards, board-washing pats dry;
(4) 100 μ L of the every hole addition sheep anti-mouse igg secondary antibody of the diluted HRP label of the PBS 1:3000 containing 0.1% gelatin, 37 DEG C reaction 0.5h after, board-washing pats dry;
(5) every hole is added 100 μ L TMB developing solutions, after 37 DEG C of colour developing 15min, 50 μ L 2M H of every hole addition2SO4Terminate liquid, 450nm surveys light absorption value;
(6) addition recycling and sample pre-treatments: taking fresh or the milk 5g of (stored refrigerated) of rising again, and adds three various doses Chlorpromazine standard items, respectively 1ng, 5ng, 10ng.It places it in 50mL centrifuge tube, is slowly dropped into 50% potassium hydroxide solution 1mL sufficiently vibrates on vortex mixer, is slowly dropped into ethyl acetate 20mL, 10min is vibrated on vortex mixer, then It is put into centrifuge and 5min is centrifuged with 3000r/min.4mL supernatant is pipetted in another centrifuge tube, is dried with nitrogen, is added The PBS that 1mL contains 10% methanol redissolves, and takes 50 μ L for detecting.Recovery test is added using indirect competitive ELISA, Its rate of recovery is respectively 98%, 92%, 105%.
The configuration of solution:
Carbonate buffer solution (CBS): Na is weighed2CO31.59g NaHCO32.93g is mixed after being dissolved in a small amount of distilled water respectively, Add distilled water to mix to about 800mL, adjusts pH value to 9.6, add distilled water to be settled to 1000mL, 4 DEG C of storages are spare;
Phosphate buffer (PBS): 8.00g NaCl, 0.2g KCl, 0.24g KH2PO4, 3.62g Na2HPO4·12 H2O, It is dissolved in 800mL pure water, with NaOH or HCl tune pH to 7.2-7.4, is settled to 1000mL;
PBST: the PBS containing 0.05% Tween20;
TMB developing solution: A liquid: Na2HPO4·12H2O 18.43g, citric acid 9.33g, pure water are settled to 1000mL;B liquid: 60 Mg TMB is dissolved in 100mL ethylene glycol.A, B liquid 1:5 mixing by volume is TMB developing solution, current existing mixed.
It is in summary only presently preferred embodiments of the present invention, practical range not for the purpose of limiting the invention.It is i.e. all Equivalent changes and modifications made by content according to the present patent application range all should be technology scope of the invention.

Claims (3)

1. hybridoma cell strain D of one plant of secretion anti-chlorine promazine monoclonal antibody, being preserved in Chinese microorganism strain preservation Administration committee common micro-organisms center CGMCC, the micro- life of the address Yard 1, BeiChen xi Road, Chaoyang District, Beijing City 3 Chinese Academy of Sciences Object research institute, classification naming are monoclonal cell strain, preservation date on May 24th, 2018, deposit number CGMCC No.17304.
2. anti-chlorine promazine monoclonal antibody, it is characterised in that: it is by deposit number CGMCC No.17304 hybridoma cell strain D Number secretion generate.
3. the application of anti-chlorine promazine monoclonal antibody described in claim 2, it is characterised in that: remaining for chlorpromazine in food Detection.
CN201910026997.0A 2019-01-11 2019-01-11 One plant of hybridoma cell strain for secreting anti-chlorine promazine monoclonal antibody and its application Withdrawn CN109705220A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910026997.0A CN109705220A (en) 2019-01-11 2019-01-11 One plant of hybridoma cell strain for secreting anti-chlorine promazine monoclonal antibody and its application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910026997.0A CN109705220A (en) 2019-01-11 2019-01-11 One plant of hybridoma cell strain for secreting anti-chlorine promazine monoclonal antibody and its application

Publications (1)

Publication Number Publication Date
CN109705220A true CN109705220A (en) 2019-05-03

Family

ID=66261258

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910026997.0A Withdrawn CN109705220A (en) 2019-01-11 2019-01-11 One plant of hybridoma cell strain for secreting anti-chlorine promazine monoclonal antibody and its application

Country Status (1)

Country Link
CN (1) CN109705220A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109022366A (en) * 2018-08-16 2018-12-18 江南大学 One plant of hybridoma cell strain for secreting anti-levamisol monoclonal antibody and its application
CN110470831A (en) * 2019-07-09 2019-11-19 华南农业大学 A kind of chemiluminescence immune analysis method and kit directly detecting tenuazonic acid based on hunchbacked source antibody

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109022366A (en) * 2018-08-16 2018-12-18 江南大学 One plant of hybridoma cell strain for secreting anti-levamisol monoclonal antibody and its application
CN110470831A (en) * 2019-07-09 2019-11-19 华南农业大学 A kind of chemiluminescence immune analysis method and kit directly detecting tenuazonic acid based on hunchbacked source antibody

Similar Documents

Publication Publication Date Title
CN105200013B (en) One plant of anti-vancocin monoclonal antibody hybridoma cell strain and its application
CN105838681B (en) One plant of anti-dexamethasone monoclonal antibody specific hybridoma cell strain C3 and its application
CN113637081B (en) Hybridoma cell strain secreting anti-pendimethalin monoclonal antibody and application thereof
CN104312978B (en) A kind of TOB monoclonal antibody and preparation method and application
CN109705220A (en) One plant of hybridoma cell strain for secreting anti-chlorine promazine monoclonal antibody and its application
US20220010029A1 (en) Hybridoma cell strain that secrets anti-dinitolmide monoclonal antibodies and the application of hybridoma cell strain
CN109280646A (en) One plant of anti-diclazuril monoclonal antibody specific hybridoma cell strain and its application
CN112574956B (en) Hybridoma cell strain secreting propamocarb monoclonal antibody and application thereof
CN107523554B (en) One plant of hybridoma cell strain SS0708 for secreting Madumycin monoclonal antibody specific and its application
CN110343669A (en) One plant of hybridoma cell strain DNC for secreting anti-Triclabendazole monoclonal antibody and its application
CN109022366A (en) One plant of hybridoma cell strain for secreting anti-levamisol monoclonal antibody and its application
CN114752568B (en) Furosemide monoclonal antibody, hybridoma cell strain and application
CN104004718B (en) One strain anti-Pirlimycin general purpose single monoclonal hybridomas cell line and application thereof
CN105907725B (en) One plant of anti-hydrocortisone monoclonal antibody specific hybridoma cell strain YH7 and its application
CN105838680B (en) One plant of anti-estriol monoclonal antibody specific hybridoma cell strain NaN-2 and its application
CN114058594B (en) Hybridoma cell strain secreting vitamin A monoclonal antibody and application thereof
CN106929479B (en) Vitamin B2 monoclonal antibody hybridoma cell strain GZ-4 and application thereof
CN107189987B (en) One plant of hybridoma cell strain YY for secreting anti-silaenafil monoclonal antibody and its application
CN105505886B (en) The anti-Ceftiofur monoclonal antibody hybridoma cell strain 2E5 of one plant of specificity and its application
CN108866010B (en) One plant of anti-furans benzene olefin(e) acid sodium monoclonal antibody hybridoma cell strain and its application
CN106636006A (en) Papaverine monoclonal antibody hybridoma cell strain YH3 and application thereof
CN106929477B (en) Anti-prostaglandin F2αSpecific monoclonal antibody hybridoma cell strain WXX-2 and application thereof
CN105907723A (en) Monoclonal antibody hybridoma cell strain YH4 resisting furaltadone metabolite AMOZ and application thereof
CN107121552B (en) One plant of hybridoma cell strain ZY-2G5-3 for secreting 3,4- methylene benzylene chloride propylamine monoclonal antibodies and its application
CN110669736A (en) Analgin monoclonal antibody hybridoma cell strain CBD and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20190503

WW01 Invention patent application withdrawn after publication